Mamot C - Search Results

1

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. Wicki A, et al. Among authors: mamot c. Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7. Clin Cancer Res. 2012. PMID: 22065082

2

Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer.

Mamot C, Mild G, Reuter J, Laffer U, Metzger U, Terracciano L, Boulay JL, Herrmann R, Rochlitz C. Mamot C, et al. Br J Cancer. 2003 Feb 10;88(3):420-3. doi: 10.1038/sj.bjc.6600733. Br J Cancer. 2003. PMID: 12569386 Free PMC article.

3

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Mamot C, et al. Cancer Res. 2003 Jun 15;63(12):3154-61. Cancer Res. 2003. PMID: 12810643

4

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Mamot C, et al. Cancer Res. 2005 Dec 15;65(24):11631-8. doi: 10.1158/0008-5472.CAN-05-1093. Cancer Res. 2005. PMID: 16357174

5

Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

Mamot C, Rochlitz C. Mamot C, et al. Swiss Med Wkly. 2006 Jan 7;136(1-2):4-12. doi: 10.4414/smw.2006.10770. Swiss Med Wkly. 2006. PMID: 16597093 Free article. Review.

6

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.

Mamot C, Ritschard R, Küng W, Park JW, Herrmann R, Rochlitz CF. Mamot C, et al. J Drug Target. 2006 May;14(4):215-23. doi: 10.1080/10611860600691049. J Drug Target. 2006. PMID: 16777680

7

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C. Mamot C, et al. J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23. J Drug Target. 2012. PMID: 22519893

8

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C. Mamot C, et al. Lancet Oncol. 2012 Dec;13(12):1234-41. doi: 10.1016/S1470-2045(12)70476-X. Epub 2012 Nov 13. Lancet Oncol. 2012. PMID: 23153506 Clinical Trial.

9

Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.

Wicki A, Wild D, Prêtre V, Mansi R, Orleth A, Reubi JC, Rochlitz C, Mamot C, Mäcke HR, Christofori G. Wicki A, et al. Among authors: mamot c. EJNMMI Res. 2014 Feb 16;4(1):9. doi: 10.1186/2191-219X-4-9. EJNMMI Res. 2014. PMID: 24528513 Free PMC article.

10

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C. Wicki A, et al. Among authors: mamot c. Int J Pharm. 2015 Apr 30;484(1-2):8-15. doi: 10.1016/j.ijpharm.2015.02.034. Epub 2015 Feb 18. Int J Pharm. 2015. PMID: 25701632

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters